About Us
1/6
Telocyte™ focuses on the development of telomerase therapy to treat Alzheimer's disease.
Our vision
Our vision is not to help anyone "live with Alzheimer's", but to ensure that all of us can live without Alzheimer's. Our vision is to cure Alzheimer's, plain and simple. We intend to save the lives, the minds, and the presence of those who have Alzheimer's now and to prevent anyone from getting Alzheimer's in future.
2/6
This is Iris, the mother of our CEO and catalyst for the founding of Telocyte™. We would like to acknowledge the wonderful care and support for Iris provided by the staff and friends at The Foundation of Lady Katherine Leveson, Temple Balsall, in the UK.
Farewell Iris, you always lead by example, facing adversity with good humour and a resolve to overcome. As a dedicated nurse, she helped many during her life, her simple request to us was that we should find a future beyond Alzheimer's for others.
That is our intention.
Our company
Telocyte™ focuses on curing Alzheimer's disease. Telocyte™ plans to run FDA-sponsored human trials to reverse Alzheimer's pathology at the cellular level. Currently, there are no effective medical or pharmaceutical interventions for those suffering from Alzheimer's disease.
3/6
We understand how Alzheimer's works and animal trials have already proven effective. With our team we have the clinical experience to begin the first-in-human trials of an effective clinical cure for Alzheimer's.
Our mission
Our mission is not to help anyone "live with Alzheimer's", but to ensure that all of us can live without Alzheimer's.
4/6
Our mission is
to cure Alzheimer's, plain and simple.
to cure Alzheimer's, plain and simple.
The Telocyte Mission:
The use of innovative advanced regenerative cell and gene therapies to reset the cell senescence that underlies and defines the "aging process". Cell senescence instigates a cascade of pathology that causes age- related disease, as our telomeres shorten and modulate the changing pattern of gene expression – the epigenetic signalling information – in aging cells. This is the fundamental problem of aging and age-related disease. To be effective, our national healthcare systems need to support the ability to maintain normal cell function as we age, both preventing age-related disease and lowering healthcare costs
Our first clinical target is Alzheimer's disease.
The use of innovative advanced regenerative cell and gene therapies to reset the cell senescence that underlies and defines the "aging process". Cell senescence instigates a cascade of pathology that causes age- related disease, as our telomeres shorten and modulate the changing pattern of gene expression – the epigenetic signalling information – in aging cells. This is the fundamental problem of aging and age-related disease. To be effective, our national healthcare systems need to support the ability to maintain normal cell function as we age, both preventing age-related disease and lowering healthcare costs
Our first clinical target is Alzheimer's disease.
Our commitment
We are committed to a cure, not to finding a symptomatic treatment, nor to finding a way to merely delay Alzheimer's by a few weeks or months. We are committed to reversing the disease process and to giving patients a return of lost function. We are committed to finding out just how much we can offer our patients.
Our commitment is founded on experience, knowledge, and hope.
Our commitment is founded on experience, knowledge, and hope.
5/6
We are committed to making lives better and to returning lives that were lost.
Hard work is not sufficient. The ability to cure a disease requires not merely hard work and resources. Clinical success requires that we first understand the fundamental disease process. We are committed to understanding in order to save lives.
Our people
Dr. Fossel is the driving force behind Telocyte™ and has been the leader in proposing the use of telomerase to treat human disease for the past two decades.
6/6
Michael Fossel MD, PhD
Founder, President
Mark Hodges is an experienced technology executive who provides effective and inspiring leadership for all Telocyte™ programs and services.
Mark Hodges
Chief Operating Officer (COO)
Peter T. Rayson is an experienced industry executive who provides leadership and business acumen for Telocyte™.
Peter Rayson
Founder,
Chief Executive Officer
Chief Executive Officer
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
Kimberley Gannon, PhD
Chief Scientific Advisor
Age-related diseases are caused by cell aging. Understanding cell aging allows us to achieve our mission: to cure Alzheimer's
Time is all we have. Taking action for A future beyond Alzheimer's is how I now choose to use mine
Lorem ipsum
The role of telomerase in aging is significant. The idea that telomerase gene therapy could be an effective treatment for Alzheimer's disease is highly intriguing.
Michael Fossel MD
PhD
Founder, President
Founder, President
Dr. Fossel is the driving force behind Telocyte™ and has been the leader in proposing the use of telomerase to treat human disease for the past two decades. Born in 1950, Michael Fossel grew up in New York, and lived in London, Palo Alto, San Francisco, Portland, and Denver. He graduated cum laude from Phillips Exeter Academy, received a joint BA and MA in psychology in four years from Wesleyan University in Connecticut, and, after completing a PhD in neurobiology at Stanford University in 1978, went on to finish his MD at Stanford Medical School in two and a half years. He was awarded a National Science Foundation Fellowship and taught at Stanford University, where he began studying aging, emphasizing premature aging syndromes. Dr. Fossel was a Clinical Professor of Medicine at Michigan State University for almost three decades and taught the Biology of Aging at Grand Valley State University. He has personal experience with a number of biotech companies, both as an inside or angel investor (Geron, Sierra Sciences), an advisor (Geron, Sierra Sciences, Phoenix Biomolecular, Betterhumans, Androcyte, PhysioAge, BioViva), and an executive (Cerner, Double Helix). He is the medical advisor for the Dementia Society of America, and has been a member of numerous scientific organizations including the American Association for the Advancement of Science, the American Aging Association (he was their executive director and served on their board of directors), the American Gerontological Society, the American Society on Aging, the American Geriatrics Society, and the Alzheimer's Association ISTAART, among others.
He has lectured at the National Institute for Health and the Smithsonian Institute, and still lectures at universities, institutes, and conferences internationally. His numerous articles on aging and ethics in the Journal of the American Medical Association, In Vivo, and other academic journals have sparked discussion and frequent calls for him to speak worldwide to both medical groups and the general public. He is frequently interviewed regarding aging by major media in the US and worldwide. He was founding editor of Rejuvenation Research. In 1996, Dr. Fossel published Reversing Human Aging, the first book to ever describe the medical aspects of extending human telomeres and the potential for curing age-related disease. The book was reviewed favorably in national full page newspaper articles and in Scientific American, as well as being published in six languages. He has appeared on Good Morning America, ABC 20/20, NBC Extra, Fox Network, CNN, the BBC, the Discovery Channel, and NPR. His magisterial academic textbook, Cells, Aging, and Human Disease, was published in 2004 by Oxford University Press.
An extensive look at the field, with well over four thousand references, it reviews the entire fields of telomere biology and cell senescence as they apply to human clinical diseases and aging. Still the only medical textbook on the clinical potential of telomerase, it includes in depth discussions of Alzheimer's disease, the progerias, atherosclerosis, osteoporosis, immune senescence, skin aging, and cancer, as well as the potential for fundamentally new therapies for these diseases using telomerase therapy. His most recent book, The Telomerase Revolution (BenBella Books, 2015), discusses aging, clinical disease, and the prospective FDA clinical trials of telomerase therapy. It has been praised in full page reviews in The London Times and The Australian, as well as being named as one of the best five science books of the year by the Wall Street Journal.
He has lectured at the National Institute for Health and the Smithsonian Institute, and still lectures at universities, institutes, and conferences internationally. His numerous articles on aging and ethics in the Journal of the American Medical Association, In Vivo, and other academic journals have sparked discussion and frequent calls for him to speak worldwide to both medical groups and the general public. He is frequently interviewed regarding aging by major media in the US and worldwide. He was founding editor of Rejuvenation Research. In 1996, Dr. Fossel published Reversing Human Aging, the first book to ever describe the medical aspects of extending human telomeres and the potential for curing age-related disease. The book was reviewed favorably in national full page newspaper articles and in Scientific American, as well as being published in six languages. He has appeared on Good Morning America, ABC 20/20, NBC Extra, Fox Network, CNN, the BBC, the Discovery Channel, and NPR. His magisterial academic textbook, Cells, Aging, and Human Disease, was published in 2004 by Oxford University Press.
An extensive look at the field, with well over four thousand references, it reviews the entire fields of telomere biology and cell senescence as they apply to human clinical diseases and aging. Still the only medical textbook on the clinical potential of telomerase, it includes in depth discussions of Alzheimer's disease, the progerias, atherosclerosis, osteoporosis, immune senescence, skin aging, and cancer, as well as the potential for fundamentally new therapies for these diseases using telomerase therapy. His most recent book, The Telomerase Revolution (BenBella Books, 2015), discusses aging, clinical disease, and the prospective FDA clinical trials of telomerase therapy. It has been praised in full page reviews in The London Times and The Australian, as well as being named as one of the best five science books of the year by the Wall Street Journal.
Peter Rayson
Founder,
Chief Executive Officer
Chief Executive Officer
Peter T. Rayson is an experienced industry executive who provides leadership and business acumen for Telocyte™.
Born in 1951 in Kettering, Northamptonshire, UK, Peter Rayson left home at the age of 16 to take up a Drawing Office Apprenticeship with Rolls-Royce Aerospace, Derby, UK. He graduated magna cum laude B.Eng (Hons) Mechanical Sciences from the University of Wales Institute of Science and Technology (UWIST) and received an M.Sc in Manufacturing Technology from the Victoria University of Manchester Institute of Science and Technology (UMIST) in 1982.
His early professional career saw management positions in Bridgeport Machines Inc. and RHP Bearings Ltd for design and development of special purpose machine tools for the automotive and aerospace industry. Whilst at UMIST he became one of the UK's first Teaching Company Associates, working with Platt Saco Lowell a large textile machinery manufacturer on Computer Aided Design and Manufacturing (CAD/CAM) Systems.
Subsequently he became Principal Lecturer at Trent Polytechnic (Nottingham Trent University) teaching undergraduates and post-graduates in mechanical engineering and advanced design and manufacturing systems. He then returned to the commercial arena as a CAD/CAM Technical Consultant for McDonnell Douglas Information Systems (MDILS), St Louis, Missouri based in UK working with many of UK's leading industry companies to implement advanced design and manufacturing systems.
Following the takeover of MDILS by EDS he was recruited by ComputerVision Inc., Boston, Mass; a global CAD/CAM vendor, to lead as their VP Aerospace Operations business in Europe. During this period he worked closely with the Directors of Rolls-Royce Aerospace to facilitate their transition to large-scale computer-aided design for the TRENT 800 engine program and support digital collaboration with Boeing on their 777 aircraft program. During this time significant technical capability was developed by ComputerVision to enable full Electronic Product Definition (EPD) of large complex engineering products.
This led to him working with Airbus Directors in Bristol, Toulouse, Hamburg and Madrid leading to the establishment of the Airbus Concurrent Engineering (ACE) facility in Toulouse to define the computer-aided design systems for the A320 aircraft program and the development of web enabled data management that is now known as Product Lifecycle Management Systems (PLMS). On the takeover of ComputerVision Inc. by PTC Inc., he became their SVP of Industry Marketing.
On returning to academe in 2000; he became a senior fellow at the University of Warwick, Warwick Manufacturing Group (WMG) working on the Ford Premium Vehicle Program, subsequently Jaguar Land Rover (JLR). He was then asked to become Associate Director of the Technology Innovation Centre (TIC), a subsidiary of Birmingham City University, UK working with JCB, Rolls-Royce, SAP and CISCO. He stepped down in 2011 to provide care for his mother who had vascular dementia and Alzheimer's disease.
Born in 1951 in Kettering, Northamptonshire, UK, Peter Rayson left home at the age of 16 to take up a Drawing Office Apprenticeship with Rolls-Royce Aerospace, Derby, UK. He graduated magna cum laude B.Eng (Hons) Mechanical Sciences from the University of Wales Institute of Science and Technology (UWIST) and received an M.Sc in Manufacturing Technology from the Victoria University of Manchester Institute of Science and Technology (UMIST) in 1982.
His early professional career saw management positions in Bridgeport Machines Inc. and RHP Bearings Ltd for design and development of special purpose machine tools for the automotive and aerospace industry. Whilst at UMIST he became one of the UK's first Teaching Company Associates, working with Platt Saco Lowell a large textile machinery manufacturer on Computer Aided Design and Manufacturing (CAD/CAM) Systems.
Subsequently he became Principal Lecturer at Trent Polytechnic (Nottingham Trent University) teaching undergraduates and post-graduates in mechanical engineering and advanced design and manufacturing systems. He then returned to the commercial arena as a CAD/CAM Technical Consultant for McDonnell Douglas Information Systems (MDILS), St Louis, Missouri based in UK working with many of UK's leading industry companies to implement advanced design and manufacturing systems.
Following the takeover of MDILS by EDS he was recruited by ComputerVision Inc., Boston, Mass; a global CAD/CAM vendor, to lead as their VP Aerospace Operations business in Europe. During this period he worked closely with the Directors of Rolls-Royce Aerospace to facilitate their transition to large-scale computer-aided design for the TRENT 800 engine program and support digital collaboration with Boeing on their 777 aircraft program. During this time significant technical capability was developed by ComputerVision to enable full Electronic Product Definition (EPD) of large complex engineering products.
This led to him working with Airbus Directors in Bristol, Toulouse, Hamburg and Madrid leading to the establishment of the Airbus Concurrent Engineering (ACE) facility in Toulouse to define the computer-aided design systems for the A320 aircraft program and the development of web enabled data management that is now known as Product Lifecycle Management Systems (PLMS). On the takeover of ComputerVision Inc. by PTC Inc., he became their SVP of Industry Marketing.
On returning to academe in 2000; he became a senior fellow at the University of Warwick, Warwick Manufacturing Group (WMG) working on the Ford Premium Vehicle Program, subsequently Jaguar Land Rover (JLR). He was then asked to become Associate Director of the Technology Innovation Centre (TIC), a subsidiary of Birmingham City University, UK working with JCB, Rolls-Royce, SAP and CISCO. He stepped down in 2011 to provide care for his mother who had vascular dementia and Alzheimer's disease.
Mark Hodges
Chief Operating Officer (COO)
Mark Hodges is an experienced technology executive who provides effective and inspiring leadership for all Telocyte™ programs and services
Born in 1952 in London UK, Mark Hodges obtained his BSc in Mechanical Engineering from Central London Polytechnic and then joined Marconi Avionics in Rochester, Kent, as a development engineer within the Airborne Display Division. During his ten years with Marconi Avionics he worked on many diverse and complex product development initiatives for a variety of aerospace and defense companies and gained substantial experience in project and program management. He also utilized computer aided engineering and design tools (CAE/CAD) as a regular part of the product development process.
Based on this experience he joined GE Calma a leading vendor of CAE & CAD tools as an application engineer and supported many of their UK and European customers. Following the acquisition of GE Calma by Prime/Computervision Inc. he became the manager of their hardware a software services business in the UK and northern Europe and had responsibility for the operational efficiency of a large team of field service engineers, spare parts distribution and management and maintenance contract revenues. After a number of successful years in this role he was asked to become the Program Manager for Computervision's largest customer Airbus Industries. In this role he was responsible for the implementation of their global concurrent engineering initiative which included the deployment of CAD, CAE & PLM (Product Lifecycle Management) tools across all of their engineering sites in the UK, Germany, France, Italy and Spain.
Following the acquisition of Computervision by PTC Inc. he held a variety of senior positions in Sales, Marketing and Consulting services before becoming the companies Chief Customer Officer. In this role he had responsibility for the global customer support organization with more than 500 engineers operating out of 15 worldwide support center locations delivering contract services to 25,000 customers. In addition, he maintained strong relationships with key strategic customers operating in the Automotive, Aerospace, High Technology, Retail and Heavy Equipment industries and implemented global processes to ensure that customer issues could be escalated and resolved as efficiently as possible and with minimum customer disruption. Success in this role led to increased responsibilities for corporate operations and culminated in 2008 with a short term role as General Manager for China Operations (based in Shanghai). He also chaired the company's Operations Council, a multi discipline group of senior managers focused specifically at improving operational efficiency, business process improvement and management of complex cross functional programs.
Mark Hodges retired from PTC Inc. in late 2014 and has been working with Telocyte since then to help formulate their business strategy, to plan and deliver corporate programs and to manage successful partner relationships.
Born in 1952 in London UK, Mark Hodges obtained his BSc in Mechanical Engineering from Central London Polytechnic and then joined Marconi Avionics in Rochester, Kent, as a development engineer within the Airborne Display Division. During his ten years with Marconi Avionics he worked on many diverse and complex product development initiatives for a variety of aerospace and defense companies and gained substantial experience in project and program management. He also utilized computer aided engineering and design tools (CAE/CAD) as a regular part of the product development process.
Based on this experience he joined GE Calma a leading vendor of CAE & CAD tools as an application engineer and supported many of their UK and European customers. Following the acquisition of GE Calma by Prime/Computervision Inc. he became the manager of their hardware a software services business in the UK and northern Europe and had responsibility for the operational efficiency of a large team of field service engineers, spare parts distribution and management and maintenance contract revenues. After a number of successful years in this role he was asked to become the Program Manager for Computervision's largest customer Airbus Industries. In this role he was responsible for the implementation of their global concurrent engineering initiative which included the deployment of CAD, CAE & PLM (Product Lifecycle Management) tools across all of their engineering sites in the UK, Germany, France, Italy and Spain.
Following the acquisition of Computervision by PTC Inc. he held a variety of senior positions in Sales, Marketing and Consulting services before becoming the companies Chief Customer Officer. In this role he had responsibility for the global customer support organization with more than 500 engineers operating out of 15 worldwide support center locations delivering contract services to 25,000 customers. In addition, he maintained strong relationships with key strategic customers operating in the Automotive, Aerospace, High Technology, Retail and Heavy Equipment industries and implemented global processes to ensure that customer issues could be escalated and resolved as efficiently as possible and with minimum customer disruption. Success in this role led to increased responsibilities for corporate operations and culminated in 2008 with a short term role as General Manager for China Operations (based in Shanghai). He also chaired the company's Operations Council, a multi discipline group of senior managers focused specifically at improving operational efficiency, business process improvement and management of complex cross functional programs.
Mark Hodges retired from PTC Inc. in late 2014 and has been working with Telocyte since then to help formulate their business strategy, to plan and deliver corporate programs and to manage successful partner relationships.
Kimberley Gannon, PhD
Chief Scientific Advisor
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Mattis est volutpat est arcu dignissim nisl, sed malesuada potenti. Egestas felis mi id eu est purus amet, aliquet. Lectus morbi congue tristique orci, quis sed. Senectus a gravida porttitor ultricies risus, nisi non. Nunc, etiam gravida integer dolor proin eu mauris. Scelerisque volutpat aliquam vulputate nisi turpis. Facilisis ligula tristique amet cum diam. Aliquet luctus id nunc nec dignissim pellentesque ultricies. Maecenas enim diam a augue semper vivamus habitant. Nam tincidunt dui augue condimentum tristique. Integer eleifend quis feugiat metus tellus pretium. Sed varius molestie vitae, varius. In dui dui quam augue et fames purus. Nisl platea faucibus cras malesuada sed. Aliquam purus cras vestibulum consequat ipsum at mattis vel. Metus urna, venenatis, dignissim quis cursus. Varius facilisis ut eget turpis in tellus leo. Augue quis lacus donec sit nulla lobortis consectetur malesuada. Viverra sed vitae neque aliquam eu suspendisse.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Mattis est volutpat est arcu dignissim nisl, sed malesuada potenti. Egestas felis mi id eu est purus amet, aliquet. Lectus morbi congue tristique orci, quis sed. Senectus a gravida porttitor ultricies risus, nisi non. Nunc, etiam gravida integer dolor proin eu mauris. Scelerisque volutpat aliquam vulputate nisi turpis. Facilisis ligula tristique amet cum diam. Aliquet luctus id nunc nec dignissim pellentesque ultricies. Maecenas enim diam a augue semper vivamus habitant. Nam tincidunt dui augue condimentum tristique. Integer eleifend quis feugiat metus tellus pretium. Sed varius molestie vitae, varius. In dui dui quam augue et fames purus. Nisl platea faucibus cras malesuada sed. Aliquam purus cras vestibulum consequat ipsum at mattis vel. Metus urna, venenatis, dignissim quis cursus. Varius facilisis ut eget turpis in tellus leo. Augue quis lacus donec sit nulla lobortis consectetur malesuada. Viverra sed vitae neque aliquam eu suspendisse.
